Answers are grounded in this paper and cite their sources.
Aim Simultaneous Islet and Kidney (SIK) transplantation aims to improve glycemic control and renal function by combining an islet transplant with a renal allograft for patients with Type 1 Diabetes Mellitus (T1DM) and renal failure. This provides diabetic improvement and removal from dialysis burden, with reduced peri-operative risk compared to solid organ simultaneous pancreas and kidney transplantation. We aimed to evaluate the outcomes of the United Kingdom’s initial cohort. Method A retrospective analysis of SIK recipients was performed between 03/2017 and 04/2023 at our hospital. Results 22 SIK were performed (72.7% donors after brain death). The mean recipient age was 56 with 54.5% female. The median diabetes duration was 42 years (IQR 22) with median post-SIK follow-up of 361 days (IQR 783). There was a median 1 infusion per recipient (median IQR 1) with median islet equivalence (IEQ) of 323,500 IEQ (IQR 141,250). HbA1c and exogenous insulin requirements were significantly lower after transplant (HbA1c: 62.7 vs 51.6mmol/mol, p<0.001; IU: 40 vs 23 units/day, p<0.001) while C-peptide significantly increased (15.9 vs 535.8pmol/l, p<0.001). Hypoglycaemic episodes/patient/year reduced (7 pre-transplant, vs 1.5 post-transplant). Median islet graft survival was 4.9 years. lgls functional classification at the end of follow-up was satisfactory (7 Optimal, 1 Good, 10 Marginal and 4 Failure). eGFR significantly increased post-SIK (15.4 vs 49mL/min/1.73m2, p<0.001). Conclusions SIK ameliorates renal failure whilst improving glycaemic control with a satisfactory complication profile. Larger and longer cohort analysis is required to fully understand the benefits of SIK for patients with complicated T1DM.
No takes yet. Share an insight, caveat, or question.
Jeyasuresh et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: